Dongwha Pharm said on the 15th that operating profit on a consolidation basis for the first quarter rose 394.8% from a year earlier to 11.2 billion won. Revenue for the same period increased 3.93% to 130.6 billion won.
The company said results improved as growth in medical devices, prescription drugs (ETC), and health and wellness was added to stable sales of existing flagship brands such as Hwalmyung-su.
Sales by product were tallied at 21.7 billion won for the Hwalmyung-su line, 15.8 billion won for the PANCOLD line, 11.6 billion won for the Itchi line, and 5.5 billion won for the Fucidin line. Subsidiaries and overseas affiliates also added support.
Medical device subsidiary Medyssey posted sales of 7.4 billion won, and Vietnam affiliate Jung Sun Pharma recorded 17.7 billion won. The company said growth of the new brand "Qurip" contributed to improved profitability.
A Dongwha Pharm official said, "Profitability improved as growth of new brands was added to stable sales of existing flagship drugs," and added, "We will strengthen competitiveness in our core businesses while continuously expanding our mid- to long-term growth base."